Key result
Pentoxifylline fails to significantly improve LVEF or exercise capacity in ischemic cardiomyopathy.
Why the study?
Abnormal blood rheology is a known characteristic of coronary artery disease, and the effects of pentoxifylline on ischemic cardiomyopathy were evaluated.
Does pentoxifylline improve exercise capacity, ejection fraction, and symptoms in patients with ischemic cardiomyopathy?
Population
9 patients with ischemic cardiomyopathy and left ventricular dysfunction with at least two major vessels obstructed
Comparison
Pentoxifylline 400 mg three times daily for twelve weeks vs baseline
Design
Case series
Authors
Loading...
Does not support clinical use in ischemic cardiomyopathy; hypothesis-generating for randomized trials.
Does pentoxifylline improve exercise capacity, ejection fraction, and symptoms in patients with ischemic cardiomyopathy?
In a small case series, pentoxifylline improved anginal symptoms and dyspnea in patients with ischemic cardiomyopathy, with non-significant trends toward improved ejection fraction and exercise tolerance.
Barnett et al. (1990) studied Ischemic cardiomyopathy (n=9). Pentoxifylline vs. Baseline was evaluated on Exercise capacity, ejection fraction and symptoms. Pentoxifylline 400 mg three times daily for 12 weeks increased mean ejection fraction by 9.8% (p=0.07) and total treadmill time by 15% (p=0.27) compared to baseline in ischemic cardiomyopathy.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: